Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Goes for Dual Listing on the Tel Aviv Stock Exchange

NEW YORK, Dec. 26 – Compugen, an Israeli bioinformatics company that trades on the Nasdaq stock exchange, said Wednesday that it had received approval to list its shares on the Tel Aviv Stock Exchange.

The move towards a dual listing is aimed at increasing interest in Compugen’s stock by providing easier access for investors in Israel to trade the company’s shares.

“The dual listing will enable Israeli and international investors, who currently do not trade shares in the US because of various restrictions, costs or time differences, to trade in Compugen stock,” the company said in a statement. “Advantages of a dual listing include a longer trading day and access to the lower trading costs on the Tel Aviv Continuous Trading system.”

Compugen said that it would become the first biotechnology company to be traded on the Tel Aviv Stock Exchange. Most Israeli high-tech companies seek to list their shares on the American or European stock exchanges, which offer bigger and more active markets.

Compugen said its shares would begin trading on the TASE on January 7.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.